Stocks making the biggest moves midday: Bed Bath & Beyond, AMC, First Solar, Palantir and more

Stocks making the biggest moves midday: Bed Bath & Beyond, AMC, First Solar, Palantir and more


An AMC theatre is pictured amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., January 27, 2021.

Carlo Allegri | Reuters

Check out the companies making headlines in midday trading.

Bed Bath & Beyond, AMC — Shares surged 41% and 13% respectively as social media traders appeared to invest in the two meme stocks, even without an apparent catalyst.

Signify Health — The stock jumped 13% following a Wall Street Journal report, citing people familiar with the matter, that CVS Health is planning a bid for the home health services company.

First Solar — First Solar jumped 5% after Goldman Sachs upgraded shares to overweight from neutral. The bank said the solar technology stock should benefit from the passage of the Inflation Reduction Act and upped its price target to $126 from $83 a share.

Rhythm Pharmaceuticals — The biopharma stock gained 7% after Goldman Sachs upgraded it to buy from neutral, saying shares could rally about 40% following successful trials of its obesity medicine.

Barrick Gold — The miner jumped 5% after beating analyst expectations in its second-quarter results, because of higher copper production.

Palantir Technologies — Shares of Palantir tumbled more than 13% after the software company known for its work with the government reported a loss of 1 cent per share in its most recent quarter. Analysts were expecting earnings of 3 cents per share, according to Refinitiv. CFO David Glazer told CNBC the company’s miss was due to a decline in investments and marketable securities.

Tyson Foods — Shares of the food products company fell 8% after Tyson missed earnings estimates in its fiscal third quarter. Company executives said on an investor call that supply chain issues were hurting its ability to fulfill customer orders, according to a transcript of the call from FactSet.

Nvidia — The semiconductor stock dropped more than 8% after Nvidia reported a revenue miss in its second-quarter results. The chipmaker generated $6.7 billion in revenue, compared to analyst expectations of $8.1 billion, citing gaming weakness.

BioNTech — The German biotech company, which partnered with Pfizer on its Covid-19 vaccine, dropped 9% after reporting earnings and revenue that missed expectations. The company said its variant-adapted Covid-19 vaccine should provide an uptick in demand in the fourth quarter.

— CNBC’s Tanaya Macheel, Jesse Pound, Samantha Subin and Michelle Fox Theobald contributed reporting



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More